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A B S T R A C T
4-Aryl-4H-Chromene derivatives have been previously shown to exhibit anti-proliferative, apoptotic and anti-
angiogenic activity in a variety of tumor models in vitro and in vivo generally via activation of caspases through
inhibition of tubulin polymerisation. We have previously identified by Virtual Screening (VS) a 4-aryl-4H-
chromene scaffold, of which two examples were shown to bind Estrogen Receptor α and β with low nanomolar
affinity and <20-fold selectivity for α over β and low micromolar anti-proliferative activity in the MCF-7 cell
line. Thus, using the 4-aryl-4H-chromene scaffold as a starting point, a series of compounds with a range of basic
arylethers at C-4 and modifications at the C3-ester substituent of the benzopyran ring were synthesised, pro-
ducing some potent ER antagonists in the MCF-7 cell line which were highly selective for ERα (compound 35;
350-fold selectivity) or ERβ (compound 42; 170-fold selectivity).
1. Introduction
Estrogen Receptors (ER) are hormone regulated receptors that are
known to produce their long-term effects on cell structure and function
via intracellular signalling and subsequent modulation of gene expres-
sion. In addition to genomic signalling, a rapid non-genomic signalling
pathway has also been identified which is mediated by cell membrane-
associated estrogen receptors. In fact a G-Protein Coupled Estrogen
Receptor (GPR30/GPER) has been identified that binds estrogen, in-
itiating a plasma membrane-initiated signaling cascade.1–4 Focusing on
‘classical’ ER, two subtypes exist and are expressed in a wide-range of
tissues and cells throughout the body; ER alpha (ERα) is predominantly
found in the female bone, uterus, ovary (thecal cells), mammaries,
adipose tissue, cardiovascular system and brain. ER beta (ERβ) is found
also in the adipose tissue, cardiovascular system and brain but also in
the lung, bladder, colon and granulosa cells of the ovary.5–14 The
concept of Selective Estrogen Receptor Modulation (SERM)15 was first
demonstrated with the clinical drug Tamoxifen16,17 which was in-
troduced in the 1970 s as a treatment for advanced breast cancer in
postmenopausal women. Tamoxifen was shown to have anti-estrogenic
function in the breast, however partial estrogenic effects in other target
tissues such as bone and the cardiovascular system where it is beneficial
but conversely harmful in the endometrium.18–21 However a strong
association between its use and the development of endometrial
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carcinoma emerged fuelling research for the discovery of alternative
compounds with mixed agonistic/antagonistic profiles (Fig. 1).
It has been since hypothesised that the optimal route to the devel-
opment of an ‘ideal’ SERM can only occur when delineation of the full
array of the biological roles orchestrated by ERα or ERβ in different
tissues is revealed, and this is best achieved through the design of
subtype-selective ER ligands. To date, a plethora of both ERα and ERβ
selective agonists and antagonists have been described (compounds
1–12, Fig. 2).22–57 The ERα agonist 16a-LE2 (1) has been reported to
inhibit cardiac hypertrophy.58 The synthesis and characterisation of a
series of pyrazole-based compounds resulted in a > 400-fold selective
agonist for ERα, 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole, (2)
(PPT).44 Mortenson et al subsequently synthesised a library of hetero-
cycle-based (furans, thiophenes, and pyrroles) ER agonists, the most
ERα selective (65-fold) of which was compound 3–2,4,5-tris(4-hydro-
xyphenyl)-3-methylfuran.39 Several SERMs have also been reported
with ERα selectivity, for example; benzothiophenes (4), tetra-
hydroisoquinolines (5)59 and pyrazoles45, with the most selective ERα
antagonist to date being a pyrazole core incorporating a basic side-
chain termed MPP (6)(~220-fold).60 To facilitate the study of ERβ
specific mechanisms of action, the first reported full agonist discovered
some time ago by Katzenellenbogen and co-workers, diarylpropionitrile
(7) (DPN), exhibited 70-fold preferential binding for ERβ over ERα and
78-fold selectivity in transcriptional assays.37 ERB-041 (Prinaberel)(8),
WAY-200070 and WAY-202196(9) were all developed by Wyeth and
reported in 2004-561–63, followed by a series of ERβ selective benzo-
pyrans developed by Lilly in 2006.41,64,65 The wide range of activities of
these compounds both in vitro and in vivo has made it particularly dif-
ficult to assign clinical relevance to them and has also been additionally
hampered by the existence of different isoforms of ERβ. ERβ1 appears
to be the isoform displaying the strongest activity, however, some
variant forms may interact with ERβ1 and also with ERα presenting a
challenge in understanding the full complexity of the biology of ERβ.66
To date, very few examples of ERβ antagonists have been reported
(Fig. 2). Two 30-fold ERβ selective antagonists have been described;
one based on a triazine scaffold (10) was discovered by GSK32 and
another by researchers at Organon67 belonging to the class of 10-aryl
substituted benzo[b]fluorenes (11). The (R,R)-cis-tetrahydrochrysene
(12) (THC) was subsequently demonstrated by the Katzenellenbogen
lab to behave as a full agonist in ERα and full antagonist in ERβ36.
Surprisingly, as THC lacks a basic side-chain, the term ‘passive antag-
onism’ was proposed for its mechanism of action supported by crystal
structures of THC bound to both ERα and ERβ ligand binding domains
(LBDs)68.
We have described in earlier work the identification by in silico
screening of a novel 4-aryl-4H-chromene scaffold which was shown to
potently bind both ER isoforms69. The two 4-aryl-4H-chromene analogs
(13 and 14) displayed modest ERα selectivity (20-fold) and also anti-
proliferative activity in an ER positive breast cancer cell line, MCF-7,
(Fig. 3). Importantly, it was noted that neither analog incorporated a
typical basic arylether and this formed the premise of the current study.
In the present work, a series of 4-aryl-4H-chromene derivatives were
designed and synthesised some of whch incorporated the typical basic
arylethers usually required in ER antagonists (Fig 2). In addition, we
have now carried out modifications at the C3 ester position of the
benzopyran ring to probe potential differences in ER binding pockets
thereby maximising isoform selectivity. The most active compound in
the series exhibited 350-fold selectivity for ERα and interestingly one of
the series showed 170-fold selectivity for ERβ. The 4-aryl-4H-chromene
scaffold has been reported in numerous studies to possess anti-pro-
liferative, apoptotic and anti-angiogenic activity in a variety of tumor
models in vitro and in vivo, generally via activation of caspases through
inhibition of tubulin polymerisation.70 In addition, the inhibition of
insulin-regulated aminopeptidase by related 4-aryl-4H-chromenes has
been recently reported.71 The 4-aryl-4H-chromene Crolibulin (15),
Fig. 3, (a microtubule destabilizing agent that disrupts vascular en-
dothelial cells, and in turn, blood flow to the tumor) is currently in
Phase I/II clinical trials assessing its toxicity levels when co-adminis-
tered with cisplatin and progression-free survival (PFS) in adults with
anaplastic thyroid cancer (ATC).72 We envisage that further
Fig. 1. Structures of selected SERM structural classes including triarylethylenes tamoxifen and endoxifen, benzothiophenes raloxifene and arzoxifene, indoles pi-
pendoxifene and bazedoxifene, benzopyran acolbifene and the tetrahydronaphthalene lasofoxifene.
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biochemical analysis of our 4-aryl-4H-chromene compound series could
potentially lead to the developement of novel clinically relevant ER




Many approaches to the preparation of 4-aryl-4H-chromenes have
Fig. 2. Subtype selective ER ligands.
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been described.71,73–76 In the present study, the synthetic route to the 4-
aryl-4H-chromenes (16–25) initially identified for the study is outlined
in Scheme 1. These compounds contain methyl ester, ethyl ester or
nitrile substituents at C-3 of the chromene ring and also benzyl, ethyl,
methyl ether or phenol substituents on the C-4 aryl ring. The appro-
priate arylaldehyde is reacted with malononitrile or the cyanoacrylate
ester and resorcinol in the presence of base (piperidine or triethyla-
mine) in a one-pot synthesis. The reaction proceeds through the for-
mation of an intermediate cyanoacrylate ester or benzylidene mal-
onitrile by Knoevenagel condensation from the cyanoacetate ester,
malonitrile and the benzaldehyde. This intermediate cyanoacrylate
ester can be observed as a solid forming within ten minutes of heating
the mixture. Further reaction of the resorcinol phenolic OH with the
nitrile and subsequent electrophilic ring closure afforded the desired
final chromene products, 16–25. The cyanoacrylate intermediate pro-
duct was isolated in the case of 26–28 and subsequently reacted with
resorcinol to afford the desired products. The phenolic methyl ester 19
was also obtained from the benzyl ether 21 by hydrogenation (H2/Pd/
C) (Scheme 1).
The series of 4-aryl-4H-chromenes containing a basic ether sub-
stituent at C-4 (compounds 24–36) were obtained as outlined in
Scheme 2. These compounds also contain methyl, ethyl, n-butyl or tert-
butyl ester or nitrile substituents at C-3 of the chromene. The benzal-
dehydes 29–31 were obtained by alkylation of 4-hydroxybenzaldehyde
with 1-(2-chloroethyl)pyrrolidine, 1-(2-chloroethyl)piperidine or 1-(2-
chloroethyl)morpholine respectively as previously reported77 to afford
the pure aldehydes in 65–97% yield. Subsequent reaction of the alde-
hydes 29–31 with malononitrile or the appropriate cyanoacrylate ester
in the presence of piperidine or triethylamine afforded desired products
32–44 in moderate yield. The cyanoacrylate intermediate 45 was also
isolated on reaction of the aldehyde 30 with ethyl cyaoacrylate and
subsequently reacted with resorcinol to afford the desired product 38.
While attempting the synthesis of the methyl esters 16, 19, 25, 32,
37, 42 using ethanol as solvent, it was noted that the final product
isolated in each case was in fact the corresponding ethyl ester 17, 20,
21, 33, 38, 43 respectively. It appeared that in the presence of ethanol,
a facile transesterification was occurring. Several different solvents
were then employed in an attempt to obtain the methyl ester products,
e.g. methanol, ethyl acetate, acetone, dichloromethane and tetra-
hydrofuran. Dichloromethane was found to be successful for the
synthesis of all other methyl ester compounds (16, 19, 25, 32, 37 and
42), however yields were low. Details of the reaction conditions for the
synthesis of compounds 16–25 and 32–44 are presented in Table 1.
Attempts to improve the yield using potassium carbonate or cetyl-
trimethylammonium chloride in aqueous conditions were not suc-
cessful.75,76 The most efficient method of preparation for the methyl
Fig. 3. 4-Aryl-4H-chromenes 13, 14 and Crolibulin (15).
Scheme 1. Synthesis of 4-aryl-4H-chromenes 16–25.
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ester products was by replacing the initially used triethylamine with
piperidine as the base of choice and by performing the reactions under
microwave conditions.
The stability of representative examples of the target compounds 38
and 40 was determined in phosphate buffer and the half life was de-
termined to be greater than24 h for each compound at pH values 7.4
and 9. The compounds 38 and 40 degraded at lower pH = 4, with 27%
and 32% remaining after 30 min respectively. The compounds showed
very high stability in human blood plasma, and the half-life was de-
termined to be greater than 24 h.
The molecular structure of a representative example of the 4-aryl-
4H-chromenes series, compound 22 was determined by single crystal X-
ray crystallography (S enantiomer shown). The ORTEP diagram is
displayed in Fig. 4 (thermal ellipsoids at 50% probability). It can be
seen that the benzopyran ring is planar, and the aryl ring at C-4 posi-
tioned at a dihedral angle of 78.403(77) ° with respect to the benzo-
pyran ring (Fig. 4).
2.2. Biological results and discussion
All compounds were initially evaluated for antiproliferative effects
in MCF-7 cells using the MTT assay (72 h) and the results are displayed
in Table 1. The most potent compound was identified as compound 41
(which contains piperidine aryl ether at C-4 and a tert-butyl ester at C-3
of the chromene ring) which showed comparative results to that of
tamoxifen in the antiproliferative assay with IC50 value of 2.65 μM (IC50
value determined for control drug tamoxifen = 4.12 μM). Compounds
16, 21, 35 and 38 also demonstrated low microlmolar antiproliferative
effects with IC50 values of 10.82, 4.50, 7.73 and 8.75 μM respectively.
Selected compounds were concurrently tested to assess the extent of
their cytotoxicity using a LDH assay. Compounds displayed negligable
cytotoxicity in LDH assay with 0% cell death observed for compounds
32, 33, 37, 38, 43 and 44.
Selected compounds from the series 16–23 and 32–44 were then
screened for their binding affinity to ERα and ERβ in a fluorescence
polarisation assay, with tamoxifen as a positive control. The results are
displayed in Table 1. For compounds 16 and 17 tested, the methyl and
ethyl ester compounds showed similar affinity to each other for ERα
and ERβ. The cyano compound 18 did not show any binding affinity for
ERα at concentrations up to 10 µM. Compound 19 with the phenolic
substituent at C-4 showed a slightly greater affinity for ERα than the
benzyloxy ether 21, however it showed markedly less affinity for ERβ.
The ethyl ether compounds 22 and the 3,4,dimethoxyether 23 having
little antiproliferative activity, were not further evaluated.
On addition of the basic ether substituent to the core phenol 20,
whether pyrolidine, piperidine or morpholine, greater ERα binding ability
was observed. For the pyrolidine containing compounds, the methyl (32),
n-butyl (35) and tert-butyl (36) esters all displayed similar affinity to ERα
with IC50 binding of less than 100 nM each (e.g. 20 nM, 20 nM and 10 nM
respectively). The ethyl ester (33) demonstrated slightly less affinity with
binding of 1.41 μM. The C-3 cyano compound 34 as observed with the
unsubstituted compounds had decreased affiniy for ERα
(IC50 = 0.89 μM), and little affinity for ERβ (IC50 > 10 μM). All com-
pounds showed selectivity for ERα over ERβ with significant difference
noted in binding affinity, this was consistent across all compounds tested.
For the compounds with the piperidine containing side chain, the methyl
(37), ethyl (38) and tert-butyl (41) esters all demonstrated good affinity to
ERα with ethyl ester compound 38 showing greatest activity with IC50
values of 20 nM and 60 nM for ERα and ERβ respectively. The tert-butyl
ester (41) which was the most active in the antiproliferative assay, also
demonstrated good affinity for ERα (IC50 = 0.090 μM) and also sub-
micromolar binding to ERβ (IC50 = 370 μM). Once again the cyano
compound 39 was the least effective in the series in the ERα and ERβ
binding assays, with IC50 values of 1.47 and 10.42 μM respectively. Of the
compounds examined containing the morpholine side-chain (42–44), the
ethyl ester 43 showed the greatest ERα binding activity (IC50 = 220 nM),
while the methyl ester 42 was the most effective as a ligand for ERβ
(IC50 = 0.63 μM).
Scheme 2. Synthesis of 4-aryl-4H-chromenes 32–44.
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2.3. Computational
To rationalise the subtype selectivity observed for compounds 35
(350-fold ERα selective) and 42 (170-fold ERβ selective) we carefully
selected the most appropriate X-ray structure to utilise for subsequent
docking experiments, through visual analysis of the binding modes
made by all co-crystallised SERMs/SERDs with their respective ER
isoforms. Lasofoxifene co-crystallised with ERα (PDBID 2OUZ) was
considered to be the most suitable LBP to dock compound 35, however,
the electron withdrawing oxygen of the morpholino-ring of 42 has the
potential to H-bond unlike the other pyrrolidine/piperidine side-chains
in the chromene series. Taking this into account, we reasoned that
PDBID 1R5K whose co-crystallised ligand GW5638, uses a bridging
water molecule that is perfectly positioned for substitution by the
morpholino-ring oxygen of 42 to enable H-bonding with the backbone
amide NeH of Leu536 (H12) would be most appropriate for docking in
this case. As no suitable ERβ isoforms of these structures existed, we
constructed refined models of each as described in the experimental
section. Briefly, the iTASSER server was used for protein structure
prediction using 2OUZ and 1R5K as templates to guide the prediction
and the co-ordinates of each were firstly morphed79 to the co-ordinates
of 2OUZ and 1R5K respectively followed by refinement using
Table 1
ERα and ERβ binding effects and antiproliferative activity in MCF-7 cells of selected 4-aryl-4H-chromenes.
Compound R1 R2 ERα IC50(µM)c,d ERβ IC50(µM)c,d β/α Antiproliferative activity MCF-7 cells IC50(µM)a,e
16 H eCO2CH3 3.30 ± 0.30 1.59 ± 0.17 0.48 10.82 ± 1.15
17 H eCO2CH2CH3 2.36 ± 1.62 0.61 ± 0.05 0.26 > 100
18 H eCN >10 8.39 ± 3.32 0.84 > 100
19 OH eCO2CH3 0.79 ± 0.40 10.02 ± 1.39 12.67 > 100
20 OH eCO2CH2CH3 nd nd - > 100
21 OCH2C6H5 eCO2CH2CH3 40.32 > 100 - 4.5
22 OCH2CH3 eCO2CH2CH3 nd nd - > 100
23 3,4-(OCH3)2 eCO2CH2CH3 nd nd - > 100
32 eCO2CH3 0.02 ± 0.02 0.35 ± 0.25 14.31 19.60 ± 20.78
33 CO2CH2CH3 1.41 ± 0.40 3.10 ± 1.57 2.21 27.29 ± 23.78
34 eCN 0.89 ± 0.19 > 10 11.23 > 50
35 eCO2CH2 CH2CH2CH3 0.02 ± 0.01 6.55 ± 2.72 353.34 7.73 ± 7.54
36 eCO2C(CH3)3 0.01 ± 0.01 0.67 ± 0.40 49.49 10.03 ± 0.48
37 eCO2CH3 0.05 ± 0.00 0.22 ± 0.14 4.77 16.2 ± 5.72
38 eCO2CH2CH3 0.02 ± 0.00 0.06 ± 0.02 2.56 8.75 ± 4.19
39 eCN 1.47 ± 0.44 10.42 ± 8.57 7.10 23.21 ± 2.81
40 eCO2(CH2)3CH3 0.03 ± 0.03 2.35 ± 0.47 87.29 31.82 ± 30.54
41 eCO2C(CH3)3 0.09 ± 0.00 0.37 ± 0.02 3.93 2.65 ± 0.15
42 eCO2CH3 109.10 ± 6.9 0.63 ± 0.03 0.0054 >100
43 eCO2CH2CH3 0.22 ± 0.02 2.44 ± 0.73 11.02 18.79 ± 21.29
44 eCN 13.97 ± 1.66 > 50 3.58 35.31 ± 10.30
Tamoxifen - - 0.070 0.170c 2.43 4.12 ± 0.038b
a IC50 values are half maximal inhibitory concentrations required to block the growth stimulation of MCF-7 cells. Values represent the mean ± S.E.M (error
values× 10−6) for at least two experiments performed in triplicate.
b The IC50 value obtained for Tamoxifen is 4.12 ± 0.038 μM is in good agreement with the reported IC50 value for tamoxifen using the MTT assay on human MCF-
7 cells [78].
c The ER binding values obtained are in agreement with the reported ER IC50 binding data for tamoxifen (ERα 60.9 nM ERβ 188 nM, Panvera/Invitrogen).
d Values are an average of at least nine replicate experiments, for ERα with typical standard errors below 15%, and six replicate experiments for ERβ, with typical
standard errors below 15%.
e 0% cell death observed for compounds 32, 33, 37, 38, 43 and 44 in LDH assay at 10 µM concentration, 13.4% cell death for tamoxifen in LDH assay at 10 µM
concentration.
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3DRefine.80 Reconstruction of any missing residues in 2OUZ and 1R5K
was also undertaken using the iTASSER server.
Conformers of all R and S enantiomers of compound 35 and 42 were
docked and in the LBP our refined models of ERα and β using FRED,81
and scored using Chemgauss4.
Marvin pKa prediction82 for compound 35 revealed the tertiary
amine of the piperidine side-chain of compound 35 is protonated at
pH7.4. Interestingly, Marvin predicted that only 15% of compound 42
would have the tertiary amine of its morpholine ring protonated at
pH7.4 with the remaining>80% predominantly neutral.
Only in the case of compound 35, was there a clear binding pre-
ference to both ER subtypes for the R enantiomer (see supplementary
information) with 1.6 and 1.9-fold differences observed in scoring for
top scoring docked poses, indicating that enantiomeric separation of the
R enantiomer might afford additional binding afffinity and selectivity.
Fig. 5 highlights the key interactions made by compound 35 in both
isoforms, and as is commonly observed with most Selective Estrogen
Receptor Modulators (SERMs), it strongly interacts with Asp351 (3 0 3)
via a salt bridge and is stabilised within the binding pocket through a
series of hydrophobic interactions (e.g. with Phe404 (3 5 6), Met343
(2 9 5)). Methionine residues are relatively unique in the protein core
whereby they can form hydrophobic interactions but also engage polar
oxygen (e.g. carbonyl) as recently reported by Pal et al.83 In the case of
compound 35, direct contact of the nucleophilic oxygen of the carbonyl
group of 35 with divalent sulfur of methionine (Met343 and Met421)
through a hypervalent nonbonded S—X interaction is apparent con-
tributing approximately 2.5 kcal/mol for this interaction.84 This inter-
action is not present in ERβ as the mutation of Met421 → Ile373 allows
35 to slightly rotate in the LBP and H-bonding with Phe346, Leu339
and Arg346 occurs rather than H-bonding to Glu353 and Arg394 ob-
served in ERα.85 This mutation has been reported by Nilsson et al.11 as
being critical in achieving subtype-selective ER based therapeutics. A
similar trend is also seen for the bulky tert-butyl moiety of 36 whereby
alpha selectivity is observed for the same reasons but to a lesser degree
than 35 (~50-fold). Interestingly, switching from the pyrrolidinyl (36)
to piperidinyl basic side-chain (41) led to a marked reduction in ERα
selectivity (> 12-fold) (Table 1). (see Fig. 6).
Compound 42 (Fig. 7) is stabilised in the binding site of both ERα
and ERβ via hydrogen bonding interactions with Glu353 (3 0 5) and
Arg394 (3 4 6) and also through additional H-bonding contacts to the
morpholino oxygen of 42 (Leu536; 2.12 Å (Val487; 2.32 Å)) and the
hydroxy group of Thr347 (2 9 9) which is well positioned to H-bond
with the morpholino tertiary amine, irrespective of its protonation
state. Interestingly, Fig. 7 highlights the additional polar contact made
between Asp303 and Tyr488 in ERβ as a result of rotation of the car-
boxylate group of Asp303 which potentially would reduce the
Fig. 4. ORTEP representation of the X-Ray crystal structure of 22, ellipsoids at 50% probability.
Fig. 5. Top ranked poses of Compound 35 in ERα (green) and ERβ (grey) indicating key hydrogen bonding interactions.
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conformational entropy of the ligand bound state of 42, translating to
an increase in binding affinity.
3. Conclusion
We have previously demonstrated the utility of the 4-aryl-4H-
chromene scaffold as a potent modulator of ER activity. Although two
4-aryl-4H-chromene analogues displayed anti-proliferative activity in
the ER positive MCF-7 cell line, ERα/β selectivity was modest.69 Fol-
lowing on from these findings, the rationale that 4-aryl-4H-chromene
analogues incorporating a typical basic side-chain could improve ERα/
β selectivity was explored. Alongside this approach, modifications at
the 3-position of the benzopyran ring were also investigated with a
view to maximising ER isoform selectivity via probing of binding pocket
topology. Several of these compounds possessed potent ER binding
activity indicative of potential ER antagonistic effects, the most active
compound (35) displayed 350-fold selectivity for ERα, whilst another
(42) showed 170-fold selectivity for ERβ. Our computational study
suggests that compound 35 achieves its selectivity in a completely
different manner to compound 42. In the case of compound 35, se-
lectivity is achieved through exploitation of the differing LBP size of
each isoform which forms as a result of the mutational differences
(Met421 → Ile373) and results in a hypervalent nonbonded S—X in-
teraction with Met343 and Met421 in ERα only. Increasing the size of
the carboxylate alkyl chain increases the binding affinity and selectivity
for ERα. Compound 42 appears to exhibit differences in interaction
potential to H12 of ERβ via Asp303 (H3) H-bonding to Tyr488 (H12)
which may stabilize the ligand bound state and reduce its conforma-
tional entropy in order to achieve this selectivity.
4. Experimental section
4.1. Chemistry
Uncorrected melting points were measured on a Gallenkamp ap-
paratus. Infra-red (IR) spectra were recorded on a Perkin Elmer FT-IR
Paragon 1000 spectrometer. 1H and 13C nuclear magnetic resonance
(NMR) spectra were recorded at 27 °C on a Brucker DPX 400 spectro-
meter (400.13 MHz, 1H; 100.61 MHz, 13C; 376.47 MHz, 19F) in either
CDCl3 (internal
standard tetramethylsilane (TMS)) or CD3OD or DMSO-d6. For
CDCl3, 1H NMR spectra were assigned relative to the TMS peak at 0.00
δ and 13C NMR spectra were assigned relative to the middle CDCl3
triplet at 77.00 ppm. For CD3OD, 1H and 13C NMR spectra were as-
signed relative to the center peaks of the CD3OD multiplets at 3.30 δ
and 49.00 ppm respectively. Coupling constants are reported in Hertz.
For 1H NMR assignments, chemical shifts are reported: shift value
(number of protons, description of absorption, coupling constant(s)
where applicable). Low resolution mass spectra were run on a Hewlett-
Packard 5973 MSD GC–MS system in an electron impact mode.
Electrospray ionisation mass spectrometry (ESI-MS) was performed in
the positive ion mode on a liquid chromatography time-of-flight mass
spectrometer (Micromass LCT, Waters Ltd., Manchester, UK). The
samples were introduced into the ion source by an LC system (Waters
Alliance 2795, Waters Corporation, USA) in acetonitrile : water (60:40
%v/v) at 200 μL/min. The capillary voltage of the mass spectrometer
was at 3 kV. The sample cone (de-clustering) voltage was set at 40 V.
Fig. 6. Side-view of top ranked poses of Compound 35 in ERα (green) and ERβ
(grey) indicating shift in orientation due to Leu384 → Met336 mutation.
Fig. 7. Top ranked poses of Compound 42 (R Enantiomer) in ERα (green) and ERβ (grey) indicating key interactions.
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For exact mass determination, the instrument was externally calibrated
for the mass range m/z 100 to m/z 1000. A lock (reference) mass (m/z
556.2771) was used. Mass measurement accuracies of< ±5 ppm were
obtained. Rf values are quoted for thin layer chromatography on silica
gel Merck F-254 plates, unless otherwise stated. Flash column chro-
matography was carried out on Merck Kieselgel 60 (particle size
0.040–0.063 mm), Aldrich aluminium oxide, (activated, neutral,
Brockmann I, 50 mesh) or Aldrich aluminium oxide, (activated, acidic,
Brockmann I, 50 mesh). Chromatographic separations were also carried
out on Biotage SP4 instrument. All products isolated were homogenous
on TLC. Microwave experiments were carried out with in the Biotage
initiator and Discover CEM microwave synthesisers.
4.1.1. General procedures for synthesis of benzopyrans.
Method A: To the appropriate aldehyde (benzaldehyde, 4-(2-pyr-
rolidin-1-ylethoxy)benzaldehyde or 4-(2-piperidin-1-ylethoxy)benzal-
dehyde) (10 mmol, 1 equiv) was added the cyanoacetate ester
(10 mmol, 1 equiv) or malononitrile (10 mmol, 1 equiv) and resorcinol
(10 mmol, 1 equiv). Ethanol (or dichloromethane for methyl ester)
(30 mL) was added and the reaction was heated briefly to reflux. The
solution was then cooled and triethylamine (0.5 mL) was added drop-
wise, and the reaction solution was then heated at reflux for 4 h.
Solvent was removed in vacuo and the product was recrystallized in
ethanol or methanol (for the methyl esters). Method B: To the appro-
priate aldehyde (4-hydroxybenzaldehyde, 4-benzyloxybenzaldehyde, 4-
ethoxybenzaldehyde, 3,4-dimethoxybenzaldehyde, 4-(2-pyrrolidin-1-
ylethoxy)benzaldehyde, 4-(2-piperidin-1-ylethoxy)benzaldehyde or 4-
(2-morpholin-1-ylethoxy)benzaldehyde)) (10 mmol, 1 equiv) was
added the cyanoacetate ester (10 mmol, 1 equiv) or malononitrile
(10 mmol, 1 equiv) and resorcinol (10 mmol, 1 equiv). Ethanol (di-
chloromethane for methyl ester) (30 mL) was added and the reaction
was heated briefly to reflux. The solution was then cooled and piper-
idine (0.5 mL) was added dropwise and the reaction solution was then
heated at reflux for 4 h. The solvent was removed in vacuo and product
was recrystallized in ethanol (or methanol for methyl esters). Method
C: To the appropriate aldehyde (4-benzyloxybenzaldehyde, 4-(2-pyr-
rolidin-1-ylethoxy)benzaldehyde, 4-(2-piperidin-1-ylethoxy)benzalde-
hyde or 4-(2-morpholin-1-yl)ethoxybenzaldehyde, (5 mmol, 1 equiv)
was added the cyanoacetate ester (5 mmol, 1 equiv) or malononitrile
(5 mmol, 1 equiv) together with resorcinol (5 mmol, 1 equiv). Ethanol
(10 mL), (dichloromethane for methyl esters) was added and the re-
action heated in the microwave reactor for 5 min. The solution was then
cooled and piperidine (0.25 mL) was added dropwise and the reaction
solution was then heated in the microwave reactor for a further 30 min.
The solvent was removed in vacuo and the product was recrystallized
from ethanol (or methanol for the methyl esters).
4.1.1.1. 2-Amino-7-hydroxy-4-phenyl-4H-chromeme-3-carboxylic acid
methyl ester (16).. Preparation following method C from
benzaldehyde (5 mmol, 0.51 mL), resorcinol (5 mmol, 550 mg) and
methyl cyanoacetate (5 mmol, 0.50 g). Yield 5.5%, yellow powder, M.p.
231 °C. IR ʋmax (KBr) cm−1: 3417.5, 3305.5 (NH2), 1664.7 (C]O)
cm−1. 1H NMR (400 MHz, CDCl3): δ 3.55 (s, 3H, O-CH3), 4.88 (s, 1H,
CH), 6.50 (d, 1H, J = 2.52 Hz, AreH), 6.55 (dd, 1H, J = 2.52 Hz,
8.4 Hz, AreH), 7.00 (d, 1H, J = 8.56 Hz, AreH), 7.06–7.09 (m, 1H,
AreH), 7.20–7.23 (m, 4H, AreH). 13C NMR (100 MHz, CDCl3): δ 39.1
(CH,), 49.4 (O-CH3), 78.1 (C), 101.8 (CH), 111.6 (CH), 117.3 (C), 125.3
(CH), 126.7 (CH), 127.7 (CH), 129.5 (CH), 149.2 (C), 156.3 (C),
160.8(C), 168.7(C]O), 168.8 (C-NH2). HRMS: Found 320.0898;
C17H15NO4Na requires 320.0899(M++Na).
4.1.1.2. 2-Amino-7-hydroxy-4-phenyl-4H-chromeme-3-carboxylic acid
ethyl ester (17).. Preparation following Method A from benzaldehyde
(10 mmol, 1.01 mL), resorcinol (1.10 g) and ethyl cyanoacetate
(10 mmol, 1.13 g). Yield 17%, white powder, M.p. 243 °C. IR ʋmax
(KBr) cm−1: 3306.4, 3300.0 (NH2), 1662.8 (C]O) cm−1. 1H NMR
(400 MHz, CDCl3): δ 1.11 (t, 3H, J = 7.02 Hz, eCH3), 2.06 (m, 2H,
NH2), 4.00 (q, 2H, J = 7.01 Hz, CH2), 4.89 (s, 1H, CH), 6.51 (d, 1H,
J = 2.64 Hz, AreH), 6.54 (dd, 1H, J = 2.52 Hz, 6.00 Hz, AreH), 7.00
(d, 1H, J = 8.00 Hz, AreH), 7.08–7.11 (m, 1H, AreH), 7.19–7.25 (m,
4H, AreH). 13C NMR (100 MHz, CDCl3): δ 13.33 (CH3), 39.21 (CH), δ
58.18 (CH2), 77.01 (C), 101.84 (CH), 111.59 (CH), 117.12 (C), 125.24
(CH), 126.87 (CH), 127.55 (CH), 129.58 (CH), 148.48 (C), 149.12 (C),
156.30 (C), 160.59(C-NH2), 168.37(C]O). HRMS: Found 334.1042;
C18H17NO4Na requires 334.1055(M++Na).
4.1.1.3. 2-Amino-7-hydroxy-4-phenyl-4H-chromeme-3-carbonitrile
(18). Preparation following Method A from benzaldehyde (10 mmol,
1.01 mL), resorcinol (1.10 g, 10 mmol) and malononitrile (10 mmol,
0.66 g). Yield 56%, Yellow powder, M.p. 246 °C73. IR ʋmax (KBr) cm−1:
3401.1 (OH), 3336.3, 3218.99 (NH2), 2180.9 (CN), 1638.46,
1624.90(C]C) cm−1. 1H NMR (400 MHz, CDCl3): δ 1.54 (s(br), 2H,
NH2), 2.76 (s(br), 1H, OH), 4.68 (s, 1H, CH), 6.51 (d, 1H, J= 2.00 Hz,
AreH), 6.57 (dd, 1H, J = 2.34 Hz, 8.76 Hz, AreH), 6.86 (d, 1H,
J = 8.76 Hz, AreH), 7.22–7.25 (m, 3H, AreH), 7.31 (d, 2H,
J = 7.6 Hz, AreH). 13C NMR (100 MHz, CDCl3): δ 40.21 (CH), 58.21
(C), 101.96 (CH), 111.99 (CH), 113.79 (CN), 118.99 (C), 126.26 (CH),
127.19 (CH), 128.08 (CH), 129.71 (CH), 145.88 (C), 148.89 (C),
156.83(CeO), 159.59 (C-NH2). HRMS: C16H12N2NaO2 requires
287.0796, found 287.0794(M++Na).
4.1.1.4. Ethyl 2-amino-7-hydroxy-4-(4-hydroxyphenyl)-4H-chromene-3-
carboxylate 20.. Preparation following the general method B above
from ethylcyanoacetate (10 mmol, 1.13 g), resorcinol (1.10 g, 10 mmol)
and 4-hydroxybenzaldehyde (10 mmol, 1.22 g). The product was
obtained as a dark brown solid which purified by flash column
chromatography over silica gel (eluent: CH2Cl2 – MeOH; 85:15) and
then recrystalised from ethanol. Yield: 1.04 g, 32%, M.p. 228-230˚C86.
IR ʋmax (KBr): 3614.49, 3595.36, (OH), 3485.10, 3357.31 (NH2),
1659.71 (C]O), 1629.41 (C]C), 1630.48 (C]C), 1591.36,
1538.14 cm−1. 1H NMR (400 MHz, DMSO-d6) δ 0.98 (t, 3H, J = 7.2,
CH3), 4.28–4.47 (m, 2H, OCH2), 4.68 (s, 1H, CH), 6.13–6.23 (m, 3H,
AreH), 6.61–6.68 (m, 2H, AreH), 6.85–6.99 (m, 2H, AreH), 8.14 (s
(br), 1H, OH), 9.15 (s (br), 2H, NH2). 13C NMR (101 MHz, DMSO-d6): δ
14.31 (CH3), 56.03 (CH), 58.49 (CH2), 76.97 (C), 101.96 (CH), 102.44
(CH), 106.17 (CH), 114.75 (C), 127.81 (CH), 129.70 (CH), 132.74 (C),
152.56 (CeO), 154.93 (C-OH), 155.24 (C-OH), 158.44 (OeCeN),
160.88 (C]O). HRMS: C18H17NNaO5 requires 350.1004, found
350.0997(M++Na).
4.1.1.5. 2-Amino-4-(4-benzyloxyphenyl)-7-hydroxy-4H-chromene-3-
carboxylic acid ethyl ester 21. Preparation following the general method
B above from ethyl cyanoacetate (10 mmol, 1.13 g), resorcinol (1.10 g,
10 mmol) and 4-benzyloxybenzaldehyde (10 mmol, 2.12 g). The
product was obtained as yellow powder which was recrystallised
from ethanol. Yield: 1.54 g, 37%. Mp 192-194˚C. IR ʋmax (KBr):
3421.76 (OH), 3304.84, 3248.32 (NH2), 1659.05 (C]O), 1610.67
(C]C), 1598.45 (C]C), 1503.32, 1454.01, 1311.69 cm−1. 1H NMR
(400 MHz, DMSO-d6): δ 1.10 (t, 3H, J = 7 Hz, CH3), 2.07 (s (br), 2H,
NH2), 3.96 (q, 2H, J = 7.04 Hz, OCH2), 4.75 (s, 1H, CH), 5.01 (s, 2H,
OCH2), 6.43 (d, 1H, J = 6.52 Hz, AreH), 6.47 (d, 1H, J = 8.04 Hz,
AreH),4 (d, 1H, J = 8.52 Hz, AreH), 6.94 (d, 2H, J = 8.52 Hz, AreH),
7.23 (d, 2H, J = 8 Hz, AreH), 7.31 (d, 1H, J = 7.04 Hz, AreH),
7.34–7.39 (m, 2H, AreH), 7.42 (d, 1H, J = 6.76 Hz, AreH), OH not
observed. 13C NMR (100 MHz, DMSO-d6): δ 14.78 (CH3), 38.58 (CH),
58.19 (CH2), 69.58 (CH2), 77.56 (C), 102.46 (CH), 112.53 (CH), 114.80
(C), 117.53 (CH), 128.08 (CH), 128.35 (CH), 128.85 (CH), 130.24 (CH),
137.68 (C), 141.58 (C), 149.51 (CeO), 156.89 (C-OH), 157.09 (CeO),
161.39 (OeCeN), 168.87 (C]O). HRMS: C25H23NNaO5 requires
440.1474, found 440.1463 (M++Na).
4.1.1.6. 2-Amino-4-(4-ethoxyphenyl)-7-hydroxy-4H-chromene-3-
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carboxylic acid ethyl ester 22. Preparation following the general method
B above from ethyl cyanoacetate (10 mmol, 1.13 g), resorcinol (1.10 g,
10 mmol) and 4-ethoxybenzaldehyde (10 mmol, 1.50 g). The product
was obtained as yellow crystals following recrystallisation from
ethanol, yield 0.78 g, 22%. M.p. 258-263˚C. IR ʋmax (KBr): 3563.54
(OH), 3431.59, 3419.15 (NH2), 1660.91 (C]O), 1634.86 (C]C),
1613.89 (C]C), 1583.43, 1568,42, 1458.83 cm−1. 1H NMR
(400 MHz, DMSO-d6): δ 1.05 (t, 3H, J = 7.04 Hz, CH3), 1.25 (t, 3H,
J = 7.02 Hz, CH3), 3.93–4.18 (m, 4H, 2xOCH2), 4.72 (s, 1H, CH),
6.42–6.50 (m, 2H, AreH), 6.73 (d, 2H, J = 9.04 Hz, AreH), 6.94 (d,
2H, J = 8.04 Hz, AreH), 7.01 (d, 1H, J = 8.12 Hz, AreH), OH not
observed, NH2 not observed. 13C NMR (100 MHz, DMSO-d6): δ 14.31
(CH3), 14.68 (CH3), 38.09 (CH), 58.51 (CH2), 62.79 (CH2), 76.81 (C),
101.97 (CH), 112.04 (CH), 113.91 (CH), 117.13 (C), 127.84 (CH),
129.76 (CH), 140.71 (C), 149.02 (CeO), 156.53 (C-OH), 160.91
(OeCeN), 168.40 (C]O). HRMS: C20H22NO5 requires 356.1498,
found 356.1488(M+ +H).
4.1.1.7. Ethyl 2-amino-7-hydroxy-4-(3,4-dimethoxyphenyl)-4H-chromene-
3-carboxylate 23. (E)-Ethyl 2-cyano-3-(3,4-dimethoxyphenyl)acrylate
28 (10 mmol, 2.62 g) and resorcinol (1.10 g, 10 mmol) were
dissolved in ethanol and the reaction mixture was briefly heated to
reflux. Piperidine (0.5 mL) was added dropwise and the reaction
solution was heated at reflux for 4 h. following the general method B
above. The solvent was removed in vacuo and product was
recrystallized from ethanol. Yield: 0.07 g, 2%, yellow crystals, M.p.
284-288˚C 71. IR ʋmax (KBr): 3488.34 (OH), 3431.11, 3412.48 (NH2),
1681.40 (C]C), 1642.76 (C]C), 1629.45 (C]O), 1562.75 cm−1. 1H
NMR (400 MHz, DMSO-d6): δ 1.09 (t, 3H, J = 7.04 Hz, CH3), 3.66 (s,
3H, OCH3), 3.71 (s, 3H, OCH3), 3.95 (q, 2H, J = 7.04 Hz, OCH2), 4.73
(s, 1H, CH), 6.42 (s, 1H, AreH), 6.46 (dd, 1H, J = 2.48, J = 7.02 Hz,
AreH), 6.55 (d, 1H, J = 9.04 Hz, AreH), 6.77 (d, 2H, J = 9.04 Hz,
AreH), 6.99 (d, 1H, J = 8.52 Hz, AreH), 7.55 (s (br), 2H, NH2), 9.57 (s
(br), 1H, OH). 13C NMR (100 MHz, DMSO-d6): δ 14.36 (CH3), 38.45
(CH), 55.40 (CH3), 58.53 (CH2), 76.72 (C), 101.97 (CH), 110.23 (CH),
111.15 (CH), 111.86 (C), 117.04 (CH), 118.64 (CH), 129.73 (CH),
141.44 (C), 146.83 (C-OCH3), 148.19 (C-OCH3), 149.03 (CeO), 156.60
(CeO), 160.97 (OeCeN), 168.43 (C]O). HRMS: C20H21NNaO6
requires 394.1267, found 394.1262(M++Na).
4.1.1.8. 2-Amino-4-(4-benzyloxyphenyl)-7-hydroxy-4H-chromene-3-
carbonitrile (24). Preparation following the general method B above
from malononitrile (0.66 g, 10 mmol) and resorcinol (1.1 g, 10 mmol)
and 4-benxyloxybenzaldehyde (2.12 g, 10 mmol). The product was
obtained as a pink solid, 2.08 g (56%) following recrystallisation from
ethanol. M.p. 264–266 °C. IR ʋmax: 3258.49 (OH), 3032.13 (CH),
2191.16 (CN), 1637.44 (C]C) cm−1. 1H NMR (400 MHz, DMSO-d6)
δ9.71 (s, 1H, OH), 7.24–7.51 (m, 5H, ArH), 7.11 (d, J = 8.54 Hz, 2H,
ArH), 6.96 (d, J = 8.54 Hz, 2H, ArH), 6.75–6.89 (m, 3H, ArH),
6.41–6.60 (m, 2H, ArH), 5.05 (s, 2H, CH2), 4.59 (s, 1H, CH). 13C NMR
(101 MHz, DMSO-d6) δ 160.2 (OeCeN), 157.2 (CeO), 157.1 (CeO),
148.8 (CeO), 138.8 (C), 137.1 (C), 130.0 (CH), 128.5 (CH), 128.4 (CH),
127.8 (CH), 127.7 (CH), 120.8 (CN), 114.8 (CH), 114.1 (CH), 112.4 (C),
102.2 (CH), 69.3 (CH2), 56.7 (C), 39.3 (CH). HRMS: C23H17N2O3
requires 369.1239; found 369.1232 [MeH]+.
4.1.1.9. 2-Amino-4-(4-benzyloxyphenyl)-7-hydroxy-4H-chromeme-3-
carboxylic acid methyl ester (25). Preparation as above using Method C
from 4-benzyloxybenzaldehyde (10 mmol, 2.12 g), resorcinol (1.10 g,
10 mmol) and methyl cyanoacetate, (10 mmol, 0.99 g). Yield 46%,
cream powder, M.p. 216–218 °C. IR ʋmax (KBr) cm−1: 3415.4, 3302.9
(NH2), 1660.7 (C]O) cm−1. 1H NMR (400 MHz, Acetone‑d6): δ 3.57 (s,
3H, O-CH3), 4.84 (s, 1H, CH), 5.04 (s, 2H, CH2), 6.50 (d, 1H,
J = 2.04 Hz, AreH), 6.55 (dd, 1H, J = 2.26 Hz, 6.04 Hz, AreH),
6.85 (d, 2H, J = 8.52 Hz, AreH), 7.00 (d, 1H, J = 8.56 Hz, AreH),
7.14 (d, 2H, J = 8.56 Hz, AreH), 7.31 (d, 1H, J = 7.04 Hz, AreH),
7.37 (t, 2H, J= 7.78 Hz, AreH), 7.44 (d, 2H, J= 7.88 Hz, AreH). 13C
NMR (100 MHz, Acetone‑d6): δ 38.2 (CH), 49.4 (O-CH3), 68.9 (O-CH2),
77.4 (C), 101.8 (CH), 111.6 (CH), 113.9 (CH), 117.6 (C), 127.1 (CH),
127.6 (CH), 127.9 (CH), 129.4 (CH), 137.2 (C), 140.8 (C), 149.2 (C),
156.2 (C), 160.6 (CeO), 160.7 (C-NH2), 168.7 (C]O). HRMS: Found
426.1297; C24H21NO5Na requires 426.1317(M++Na).
4.1.2. 2-Amino-7-hydroxy-4-(4-hydroxyphenyl)-4H-chromeme-3-
carboxylic acid methyl ester (19)
2-Amino-4-(4-benzyloxyphenyl)-7-hydroxy-4H-chromene-3-car-
boxylic acid methyl ester (25) (1.6 mmol, 0.77 g) was dissolved in ethyl
acetate (20 mL) and Pd/C (10%, 0.8 g) was added. The mixture was
stirred under an atmosphere of hydrogen for 12 h until reaction was
complete as monitored by TLC. The catalyst was removed by filtrations
and the residue was purified by chromatography to afford the product
as a waxy solid, IR: KBr ʋmax: 3415.4, 3302.9 (NH2), 1660.7 (C]O)
cm−1. 1H NMR (400 MHz, CDCl3): δ 3.57 (s, 3H, O-CH3), 4.79 (s, 1H,
CH), 6.49 (d, 1H, J = 2.00 Hz, AreH), 6.56 (dd, 1H, J = 2.02 Hz,
6.00 Hz, AreH), 6.69 (d, 2H, J = 8.52 Hz, AreH), 6.99–7.04 (m, 3H,
AreH). 13C NMR (100 MHz, CDCl3): δ 38.2 (CH), 49.4 (O-CH3), 68.9
(O-CH2), 77.4 (C), 101.8 (CH), 111.6 (CH), 113.9 (CH), 117.6 (C),
127.1 (CH), 127.6 (CH), 127.9 (CH), 129.4 (CH), 137.2 (C), 140.8 (C),
149.2 (C), 156.2 (C), 160.6 (CeO), 160.7 (C-NH2), 168.7 (C]O). Found
336.0852; C17H15NO5Na requires 336.0848(M++Na).
4.1.3. General procedure for synthesis of cyanoacrylate esters 26–28
A solution of methyl or ethyl cyanoacetate (10 mmol) and the ap-
propriate arylaldehyde (10 mmol) in methanol 30 mL was heated
briefly to reflux. The solution was cooled and piperidine (0.5 mL) was
added dropwise and the reaction solution was then heated at reflux for
4 h. The solution was cooled and the solvent was removed in vacuo and
product was recrystallized from ethanol.
4.1.3.1. (E)-Methyl 2-cyano-3-(4-hydroxyphenyl)acrylate 26. A mixture
of methyl cyanoacetate (10 mmol, 1.13 g) and 4-hydroxybenzaldehyde
(10 mmol, 1.22 g) was melted under vacuum in a Kugelrohr short-path
vacuum distillation apparatus at 170 °C for 40 min. The product was
then dried at 80 °C and then recrystallized from ethanol as beige
coloured crystals. Yield: 1.802 g, 90%, Mp: 208–210 °C.69 IR vmax (KBr):
3415.50 (OH), 2224.80 (CN), 1725.19 (C]O), 1589.33 (C]C) cm−1.
1H NMR (400 MHz, DMSO-d6): 3.78 (s, 3H, OCH3), 6.91 (d,
J = 8.54 Hz, 2H), 7.94 (d, J = 9.16, Hz, 2H), 8.18 (s, 1H, CH]C).
13C NMR (100 MHz, CDCl3): δ 51.99 (OCH3), 97.62 (C), 115.53 (CN),
115.88 (CH), 123.06 (C), 133.50 (CH), 153.89 (CH), 162.08 (C-OH),
162.76 (C]O).
4.1.3.2. (E)-Ethyl 2-cyano-3-(4-benzyloxyphenyl)acrylate 27. Following
the procedure outlined above, a solution of ethyl cyanoacetate
(10 mmol, 1.13 g) and 4-benzyloxybenzaldehyde (10 mmol, 2.12 g)
in benzene (20 mL) was heated briefly to reflux and then cooled.
Piperidine (0.99 mL) was added dropwise and the reaction solution was
then heated at reflux for 4 h. The solution was washed with HCl (10%)
and then extracted with dichloromethane. The solvent was removed in
vacuo and the product was recrystallized from ethanol as cream
coloured crystals. Yield: 2.53 g, 83%, M.p. 99–100 °C 87. IRvmax
(KBr): 2221.96 (CN), 1714.07 (C]O), 1688.82 (C]C), 1563.74,
1473.48 cm−1. 1H NMR (400 MHz, CDCl3): 1.40 (t, J = 7.02 Hz, 3H,
CH3), 4.38 (q, J = 7.12 Hz, 2H, CH2), 5.16 (s, 2H, CH2), 7.07 (d,
J= 9.16 Hz, 2H, ArH), 7.32–7.47 (m, 5H, ArH), 8.01 (d, J= 8.54 Hz,
2H, ArH), 8.18 (s, 1H, CH]C).
4.1.3.3. (E)-Ethyl 2-cyano-3-(3,4-dimethoxyphenyl)acrylate 28. Following
the procedure outlined above, a solution of ethyl cyanoacetate (10 mmol,
1.13 g) and 3,4-dimethoxybenzaldehyde (10 mmol, 1.66 g) in ethanol
30 mL was heated briefly to reflux and then cooled. Piperidine (0.5 mL)
was then added dropwise and the reaction solution heated at reflux for
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4 h. The solvent was removed in vacuo and product was recrystallized
from ethanol to afford the product as yellow crystals. Yield: 0.34 g, 13%,
M.p. 160 °C 41. IR ʋmax (KBr): 2244.68 (CN), 1673.71 (C]C), 1643.64
(C]O), 1563.74, 1473.48 cm−1. 1H NMR (400 MHz, DMSO-d6): δ 0.94
(t, 3H, J = 7.14 Hz, CH3), 3.72 (s, 6H, 2xOCH3), 3.86 (q, 2H, J = 7.04,
CH2), 6.38 (d, 1H, J = 2.28, AreH), 6.45 – 6.51 (m, 1H, AreH),
7.18–7.27 (m, 1H, AreH), 8.46 (d, 1H, J = 6.98, CH). 13C NMR
(100 MHz, DMSO-d6): δ 14.33 (CH3), 58.85 (OCH3), 62.03 (CH2), 78.01
(C), 106.63 (CH), 112.53 (CN), 120.75 (CH), 128.77 (C), 148.70 (C-
OCH3), 149.77 (C-OCH3), 157.73 (CH), 168.72 (C]O). HRMS:
C14H16NO4 requires 262.1079, found 262.1086(M+ +H).
4.1.4. General procedure for preparation of 29–31
4-Hydroxybenzaldehyde (16 mmol (1 equiv)) was dissolved in ethyl
acetate (20 mL). To this solution was added anhydrous potassium
carbonate (18 mmol, 2.50 g) (1.125 equiv) and tetra-n-butylammonium
bromide (0.054 g, 0.2 mmol). The mixture was then heated at reflux for
10 min and the appropriate basic ether was then added (32 mmol, 2
equiv). [The basic ethers 1-(2-chloroethyl)pyrrolidine, 1-(2-chlor-
oethyl)piperidine and 1-(2-chloroethyl) morpholine were obtained as
their HCl salt and were washed with water (45 mL) and sodium hy-
droxide (10.5 g) in toluene (6 mL) to extract the free base for use in the
reaction]. The reaction mixture was heated at reflux until reaction was
complete as monitored by thin layer chromatography. On completion,
the solution was filtered and the solvent was removed under reduced
pressure to afford product, which was used in the following reactions
without further purification.
4.1.4.1. 4-(2-Pyrrolidin-1-ylethoxy)benzaldehyde (29). The preparation
was according to the general procedure above. The product was
isolated as orange oil77 yield 65%. 1H NMR (400 MHz, CDCl3): δ 1.59
(s, 4H, (CH2)2), 2.41 (s, 4H, CH2eNeCH2), 2.70 (2H, t, J = 5.78 Hz,
–CH2), 3.96 (t, J = 5.78 Hz, 2H, O-CH2), 6.79 (d, 2H, J = 8.56 Hz,
AreH), 7.58 (d, 2H, J = 8.52 Hz, AreH), 9.64 (s, 1H, CHO).
4.1.4.2. 4-(2-Piperidin-1-ylethoxy)benzaldehyde (30). The preparation
was according to the general procedure above (32 mmol scale). The
product was isolated as orange coloured oil, (5.42 g, 73%)77. 1H NMR
(400 MHz, CDCl3): δ 1.53–1.55 (m, 6H, 3xCH2), 2.51–2.66 (m, 6H,
CH2), 4.29–4.36 (m, 2H, CH2), 7.13 (d, 2H, J= 8.0 Hz, AreH), 7.85 (d,
2H, J = 8.0 Hz, AreH), 9.89 (s, 1H, CHO).
4.1.4.3. 4-(2-Morpholin-1-ylethoxy)benzaldehyde (31). The preparation
was according to the general procedure above and the product was
isolated as an orange coloured oil (97%)77. 1H NMR (400 MHz, CDCl3):
δ 2.60 (m, 4H, 2xCH2), 2.68 (s, 2H, CH2), 3.56 (m, 4H, 2xCH2), 4.05 (m,
2H, 2xO-CH2), 6.86 (m, 2H, AreH), 7.67 (m, 2H, AreH), 9.71 (s, 1H,
CHO).
4.1.4.4. 2-Amino-7-hydroxy-4-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-4H-
chromeme-3-carboxylic methyl ester (32). Preparation was as described
above from 4-(2-pyrrolidin-1-ylethoxy)benzaldehyde (29) (10 mmol,
2.19 g), resorcinol (1.10 g, 10 mmol) and methyl cyanoacetate
(10 mmol, 0.99 g), using general Method C. Yield 10%, M.p. 167 °C,
yellow crystals. IR νmax (KBr) cm−1: 3413.53, 3296.89 (NH2),
1701.9(C]O), 1656.4, 1610.6(C]C) cm−1. 1H NMR (400 MHz,
CDCl3): δ 1.74–1.77 (m, 4H, C-(CH2)2-C), 2.64–2.67 (m, 4H,
CH2eNeCH2), 2.87–2.90 (t, 2H, J = 5.88 Hz, CH2eN), 3.57 (s, 3H,
O-CH3), 4.05–4.08 (t, 2H, J = 5.90 Hz, CH2eN), 4.83 (s, 1H, CH),
6.50–6.51 (d, 2H, J= 2.52 Hz, AreH), 6.54–6.57 (dd, 1H, J= 2.36 Hz,
6.04 Hz, AreH), 6.77–6.79 (d, 2H, J= 8.76 Hz, AreH), 6.99–7.02 (m,
1H, AreH), 7.11–7.13 (d, 2H, J= 8.52 Hz, AreH). 13C NMR (151 MHz,
DMSO-d6) δ 161.5 (Ar-C), 156.9 (Ar-C), 149.4 (Ar-C), 141.0 (Ar-C),
128.0 (Ar-CH), 117.6 (Ar-CH), 114.4 (Ar-CH), 112.4 (Ar-CH), 102.4
(Ar-CH), 77.0 (-C-), 66.9 (NCH2), 54.7 (OCH3), 54.3 (NCH2), 40.37
(CH), 38.3 (CH2), 23.4 (CH2). HRMS: Found 411.1927; C23H27N2O5
requires 411.1920(M++H).
4.1.4.5. 2-Amino-7-hydroxy-4-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-4H-
chromeme-3-carboxylic acid ethyl ester (33). Preparation was as
described above from 4-(2-pyrrolidin-1-ylethoxy)benzaldehyde (29)
(10 mmol, 2.19 g), resorcinol (1.10 g, 10 mmol) and ethyl
cyanoacetate (10 mmol, 1.13 g) using Method B. Purification was
achieved by flash column chromatography over silica gel (eluent:
dichloromethane:methanol; 9:1) to afford the product as a yellow gel,
yield 10%. IR ʋmax (film) 1671.15 (C]O) cm−1. 1H NMR (400 MHz,
CDCl3): δ 1.15 (t, 3H, J= 7.28 Hz, eCH3), 1.76–1.90 (m, 4H, C-(CH2)2-
C), 2.03–2.07 (m, 4H, CH2eNeCH2), 2.93–2.94 (t, 2H, J = 5.78 Hz,
CH2eN), 4.01–4.06 (q, 2H, J = 7.02 Hz, CH2eN), 4.22–4.24 (t, 2H,
J= 4.76 Hz, O-CH2), 4.80 (d, 1H, CH), 5.12 (bs, 1H, OH), 6.47–6.49 (d,
2H, J= 3 Hz, AreH), 6.85–6.90 (dd, 3H, J= 5.04 Hz, 8.78 Hz, AreH),
7.14 (d, 2H, J= 9.04 Hz, AreH). 13C NMR (100 MHz, CDCl3): δ 13.09
(CH3), 22.14 (CH2), 38.40 (CH), 53.32 (CH2), 53.84 (CH2), 58.53
(CH2), 62.56 (CH2), 77.09 (C), 101.73 (Ar-CH), 111.44 (Ar-CH), 113.62
(Ar-CH), 116.96 (ArC), 127.76 (Ar-CH), 129.22 (Ar-C), 131.38 (Ar-C),
129.88 (Ar-CH), 138.48 (Ar-C), 148.92 (Ar-C), 155.48 (AreCeO),
156.12 (AreCeO), 162.50 (AreCeN), 169.209 (C]O). HRMS: Found
425.2081; C24H29N2O5 requires 425.2076(M++H).
4.1.4.6. 2-Amino-7-hydroxy-4-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-4H-
chromeme-3-carbonitrile (34). Preparation following General Method B
from 4-(2-pyrrolidin-1-ylethoxy)benzaldehyde (29) (1.3 mmol,
0.285 g), resorcinol (143 mg, 1.30 mmol) and malononitrile
(1.3 mmol, 85.9 mg). Yield 20.4%, M.p. 181 °C, cream powder. IR
ʋmax (KBr) 3439.6, 3360.1 (NH2), 2185.1 (CN) cm−1. 1H NMR
(400 MHz, CDCl3): δ 1.74 (s, 4H, C-(CH2)2-C), 2.64 (t, 4H,
J = 5.10 Hz, CH2eNeCH2), 2.80 (t, 2H, J = 6.02 Hz, CH2eN), 4.01
(t, 2H, J= 6.04 Hz, CH2eN), 4.55 (s, 1H, CH), 6.10 (bs, 1H, OH), 6.38
(d, 1H, J= 2.36 Hz, AreH), 6.46 (dd, 1H, J= 2.56 Hz, AreH), 6.78 (d,
1H, J = 8.48 Hz, AreH), 6.85 (d, 2H, J = 4.96 Hz, AreH), 7.13–7.15
(d, 2H, J= 8.52 Hz). 13C NMR (100 MHz, CDCl3): δ 23.12 (CH2), 26.45
(CH2), 38.15 (CH), 46.66 (CH2), 53.97 (CH2), 54.35 (CH2), 56.52 (C),
66.63 (CH2), 102.09 (Ar-CH), 106.15 (CH), 112.35 (CH), 113.94 (C),
114.40 (CH), 120.75 (CH), 128.42 (CH), 129.88 (CH), 138.48 (C),
148.76 (C), 157.13 (C), 157.22 (C), 158.49 (CeO), 160.09 (CeN).
HRMS: Found 378.1801; C22H24N3O3 requires 378.1818(M++H).
4.1.4.7. 2-Amino-7-hydroxy-4-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-4H-
chromeme-3-carboxylic n-butyl ester (35). Preparation following the
general Method A from 4-(2-pyrrolidine-1-yl-ethoxy)-benzaldehyde
(29) (2.5 mmol, 0.547 g), resorcinol (2.5 mmol, 280 mg), and n-butyl
cyanoacetate (2.5 mmol, 353 mg). Yield 14.2%, yellow powder. IR ʋmax
(KBr) cm−1. 3407.44, 3294.68 (NH2), 1673.91 (C]O) cm−1. 1H NMR
(400 MHz, DMSO-d6): δ 0.78 (t, 1H, J = 7.54 Hz, CH2), 1.06 (t, 3H,
J = 3.52 Hz, CH3), 1.40 (m, 1H, CH2), 1.66 (bs, 4H, (CH2)2), 2.51 (d,
6H, J= 11.04 Hz, (CH2)3), 2.73 (t, 2H, J= 5.76 Hz, NeCH2), 3.71 (m,
4H, 2 × O-CH2), 4.73 (s, 1H, CH), 6.42 (d, 1H, J = 2.17 Hz, AreH),
6.48 (dd, 1H, J = 2.24 Hz, 6.04 Hz, AreH), 6.78 (d, 2H, J = 8.52 Hz,
AreH), 6.99 (d, 1H, J= 8.28 Hz, AreH), 7.03 (m, 2H, AreH). 13C NMR
(100 MHz, DMSO-d6): δ 14.32 (CH3), 18.56 (CH2), 23.10 (CH2), 30.50
(CH2), 38.10 (CH), δ 53.95 (CH3), 54.30 (CH2), 54.32 (CH2), 58.52
(CH2), 62.20 (CH2), 66.50 (CH2), 76.81 (C), 101.97 (CH), 112.04 (CH),
113.98 (CH), 117.05 (C), 127.74 (CH), 127.86 (CH), 129.75 (CH),
140.83 (C), 148.85 (CH), 149.02 (C), 156.51 (C), 156.61 (C), 160.91
(C), 160.99 (C), 168.49 (C]O). HRMS: Found 453.2393; C26H33N2O5
requires 453.2389(M++H).
4.1.4.8. 2-Amino-7-hydroxy-4-[4-(2-pyrolidine-1-ylethoxy)phenyl]-4H-
chromeme-3-carboxylic tert-butyl ester (36). Preparation following
general method A above from 4-(2-pyrrolidine-1-yl-ethoxy)
benzaldehyde (29) (2.5 mmol, 0.547 g), resorcinol (2.5 mmol,
280 mg) and tert-butyl cyanoacetate (2.5 mmol, 353 mg). Yield 63%,
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white powder. IR ʋmax (KBr) cm−1: 3407.03, 3291.65 (NH2), 1672.28
(C]O) cm−1. 1H NMR (400 MHz, DMSO-d6): δ 1.36 (s, 9H, (CH3)3),
1.78 (s, 4H, (CH2)2), 2.47 (bs, 4H, (CH2)2), 2.72 (t, 2H, J = 6.04 Hz,
CH2), 3.97 (t, 2H, J = 5.78 Hz, CH2), 4.65 (s, 1H, CH), 6.39 (d, 1H,
J = 2.48 Hz, AreH), 6.44 (dd, 1H, J= 2.26 Hz, 8.52 Hz, AreH), 6.77
(d, 2H, J= 8.52 Hz, AreH), 6.93 (d, 1H, J= 8.56 Hz, AreH), 7.01 (d,
2H, J= 8.52 Hz, AreH). 7.48 (s, 2H, NH2), 9.57 (s, 1H, OH). 13C NMR
(100 MHz, DMSO-d6): δ 23.11 (CH2), 28.10 (CH3), 38.58 (CH), 53.99
(CH2), 54.34 (CH2), 56.03 (CH2), 66.59 (CH2), 77.86 (C), 78.01 (C),
101.90 (CH), 111.92 (CH), 113.90 (CH), 116.93 (C), 127.88 (CH),
129.82 (CH), 141.19 (C), 148.85 (C), 156.46 (C), 156.52 (C), 160.81
(C), 168.50 (C]O). HRMS: Found 453.2393; C26H33N2O5 requires
453.2389(M++H).
4.1.4.9. 2-Amino-7-hydroxy-4-[4-(2-piperidin-1-ylethoxy)phenyl]-4H-
chromeme-3-carboxylic methyl ester (37). Preparation following the
general method C above from 4-(2-piperidine-1-ylethoxy)-
benzaldehyde (30) (5 mmol, 1.16 g) and methyl cyanoacetate
(5 mmol, 495 mg) and resorcinol (5 mmol, 560 mg). Yield 25%, M.p.
180–181 °C, yellow powder. IR ʋmax (KBr) cm−1: 3400.00, 3299.51
(NH2), 1660.34 (C]O) cm−1. 1H NMR (400 MHz, DMSO-d6): δ 1.35 (d,
2H, J= 4.88 Hz, CH2), 1.46 (t, 4H, J= 5.38 Hz, (CH2)2), 2.39 (bs, 4H,
(CH2)2), 2.51 (t, 2H, J = 1.96 Hz, CH2), 3.51 (s, 3H, O-CH3), 3.96 (t,
2H, J = 5.86 Hz, CH2), 4.75 (s, 1H, CH), 6.44 (d, 1H, J = 2.44 Hz,
AreH), 6.48 (dd, 1H, J = 2.20 Hz, 6.36 Hz, AreH), 6.78 (d, 2H,
J = 8.80 Hz, AreH), 6.99 (d, 1H, J = 8.32 Hz, AreH), 7.03 (d, 2H,
J = 8.80 Hz, AreH). 13C NMR (100 MHz, DMSO-d6): δ 24.39 (CH2),
26.03 (CH2), 38.47 (CH), 50.86 (CH3), 54.85 (CH2), 57.89 (CH2), 65.85
(CH2), 77.07 (C), 102.50 (CH), 112.52 (CH), 114.58 (CH), 117.79 (C),
128.12 (CH), 130.07 (CH), 141.08 (C), 149.54 (C), 157.08 (C), 161.64
(C), 169.20 (C]O). HRMS: Found 425.2082; C24H29N2O5 requires
425.2076(M++H).
4.1.4.10. 2-Amino-7-hydroxy-4-[4-(2-piperidin-1-ylethoxy)phenyl]-4H-
chromeme-3-carboxylic ethyl ester (38). (i) Following the method
outlined above for 28, a solution of ethyl cyanoacetate (10 mmol,
1.13 g) and 4-(2-piperidin-1-ylethoxy)benzaldehyde (30) (10 mmol,
2.33 g) in ethanol (30 mL) was heated briefly to reflux and then cooled.
Piperidine (0.5 mL) was then added dropwise and the reaction solution
heated at reflux for 4 h. The solvent was removed in vacuo to afford the
product (E)-ethyl 2-cyano-3-[4-(2-piperidin-1-ylethoxy)phenyl]acrylate
45 which was recrystallized from ethanol as orange coloured crystals
and used immediately in the next reaction. Yield: 334 mg, 10.2%, M.p.
88–90 °C. IR ʋmax (KBr): 2213(CN), 1702(C]O), 1610(C]C) cm−1. 1H
NMR (400 MHz, CDCl3): δ 8.06 (s, 1H, CH]C), 7.92 (d, J = 9.16 Hz,
2H, ArH), 6.86 (d, J = 8.54 Hz, 2H, ArH), 4.34 (q, J = 7.12 Hz, 2H,
OCH2), 3.45 (br. s., 4H, 2xCH2), 1.69 (br. s., 6H, 3xCH2), 1.38 (t,
J = 7.32 Hz, 3H, OCH2CH3). 13C NMR (100 MHz, CDCl3): δ 14.26
(CH3), 24.31 (CH2), 25.32 (CH2), 48.10 (CH2), 61.90 (CH2), 94.64
(C]CH), 113.24 (CH), 117.38 (CN), 120.08 (C), 134.06 (CH), 154.01
(C), 154.21 (CH]C), 164.14 (C]O). (ii) Preparation following the
general method B above from (E)-ethyl 2-cyano-3-[4-(2-piperidin-1-
ylethoxy)phenyl]acrylate 45 (10 mmol, 2.33 g) and resorcinol
(10 mmol, 1.13 g). Yield 20%, M.p. 176–178 °C, yellow powder. IR
ʋmax (KBr) cm−1: 3415.04, 3293.18 (NH2), 1672.17 (C]O) cm−1. 1H
NMR (400 MHz, DMSO-d6): δ 1.04 (m, 9H, CH3, CH2), 1.98 (m, 4H,
CH2), 2.78 (2H, CH2), 3.94 (t, 4H, J= 6.13 Hz, CH2), 4.74 (s, 1H, CH),
6.44 (d, 1H, J = 2.44 Hz, AreH), 6.48 (dd, 1H, J = 2.44 Hz, 5.88 Hz,
AreH), 6.69 (d, 2H, J = 8.80 Hz, AreH), 6.88 (d, 1H, J = 8.32 Hz,
AreH), 7.02 (d, 2H, J = 6.84 Hz, AreH), 7.09 (d, 1H, J = 8.80 Hz,
AreH). 13C NMR (100 MHz, DMSO-d6): δ 14.32 (CH3), 23.92 (CH2),
25.55 (CH2), 38.09 (CH), 54.39 (CH2), 57.41 (CH2), 58.52 (CH2), 65.39
(CH2), 76.81 (C), 101.99 (CH), 112.05 (CH), 114.02 (CH), 117.12 (C),
127.85 (CH), 129.75 (CH), 140.82(C), 149.02 (C), 156.53 (C), 156.60
(C), 160.91 (C), 168.39 (C]O). HRMS: Found 439.2227; C25H31N2O5,
requires 439.2233(M++H).
4.1.4.11. 2-Amino-7-hydroxy-4-[4-(2-piperidin-1-ylethoxy)phenyl]-4H-
chromeme-3-carbonitrile (39). Preparation as described for 38 above
from 4-(2-piperidine-1-ylethoxy)benzaldehyde (30) (5 mmol, 1.16 g),
malononitrile (5 mmol, 330 mg) and resorcinol (5 mmol, 560 mg)
following method A. Yield 35%, M.p. 194–196 °C, beige powder. IR
ʋmax (KBr) cm−1: 3401.16, 3300.00 (NH2), 2186.78 (CN) cm−1. 1H
NMR (400 MHz, DMSO-d6): δ 1.43 (m, 2H, CH2), 1.56 (m, 4H, CH2),
2.48 (m, 4H, CH2), 2.68 (t, 2H, J = 6.02 Hz, NeCH2), 4.07 (t, 2H,
J = 6.04 Hz, O-CH2), 4.63 (s, 1H, CH), 6.52 (d, 1H, J = 2.48 Hz,
AreH), 6.60 (dd, 1H, J= 2.52 Hz, 6.00 Hz, AreH), 6.78 (s, 1H, AreH),
6.87 (dd, 2H, J = 2.34 Hz, 4.48 Hz, AreH), 7.15 (m, 2H, AreH). 13C
NMR (100 MHz, DMSO-d6): δ 24.39 (CH2), 26.03 (CH2), 38.47 (CH),
50.86 (CH3), 54.85 (CH2), 57.89 (CH2), 65.85 (CH2), 77.07 (C), 102.50
(CH), 112.52 (CH), 114.58 (CH), 117.79 (C), 128.12 (CH), 130.07 (CH),
141.08 (C), 149.54 (C), 157.08 (C), 161.64 (C), 169.20 (C]O). HRMS:
Found 392.1957; C23H26N3O3 requires 392.1974(M++H).
4.1.4.12. 2-Amino-7-hydroxy-4-[4-(2-piperidin-1-ylethoxy)phenyl]-4H-
chromeme-3-carboxylic n-butyl ester (40). Preparation as described for
39 above from 4-(2-piperidine-1-ylethoxy)benzaldehyde (30) (5 mmol,
1.16 g), n-butylcyanoacetate (5 mmol, 705.8 mg) and resorcinol
(5 mmol, 560 mg) using general method A. Yield 13%, M.p. 158 °C,
yellow powder. IR ʋmax (KBr) cm−1: 3415.93, 3294.68 (NH2), 1672.10
(C]O) cm−1. 1H NMR (400 MHz, DMSO-d6): δ 1.06 (t, 3H,
J = 7.02 Hz, CH2), 1.45 (m, 8H, (CH2)4), 2.40 (bs, 4H, (CH2)2), 2.51
(s, 2H, CH2), 2.60 (t, 2H, J = 5.52 Hz, NeCH2), 3.95 (m, 4H, (CH2)2),
4.73 (s, 1H, CH), 6.42 (d, 1H, J = 2.48 Hz, AreH), 6.46 (dd, 1H,
J= 2.28 Hz, 6.00 Hz, AreH), 6.78 (d, 2H, J= 8.52 Hz, AreH), 6.93 (d,
1H, J = 8.52 Hz, AreH), 7.01 (d, 2H, J = 8.52 Hz, AreH). 13C NMR
(100 MHz, DMSO-d6): δ 14.32 (CH3), 23.88 (CH2), 25.50 (CH2), 30.51
(CH2), 38.10 (CH), 54.36 (CH3), 56.03 (CH2), 57.36 (CH2), 58.52
(CH2), 62.20 (CH2), 65.35 (CH2), 76.82 (C), 101.99 (CH), 106.17 (CH),
112.06 (CH), 114.03 (CH), 117.09 (C), 127.73 (CH), 129.74 (CH),
140.84 (C), 149.02 (C), 156.52 (C), 158.45 (C), 160.91 (C), 168.39 (C]
O). HRMS: Found 467.2558; C27H35N2O5 requires 467.2546(M++H).
4.1.4.13. 2-Amino-7-hydroxy-4-[4-(2-piperidin-1-ylethoxy)phenyl]-4H-
chromeme-3-carboxylic tert-butyl ester (41). Preparation as described for
39 above from 4-(2-piperidine-1-ylethoxy)benzaldehyde (30)
(2.5 mmol, 0.583 g), tert-butycyanoacetate (2.5 mmol, 360 mg) and
resorcinol (5 mmol, 560 mg) using general Method A. Yield 27%,
colourless oil. IR ʋmax (KBr) cm−1: 3415.98, 3289.85 (NH2), 1672.28
(C]O) cm−1. 1H NMR (400 MHz, DMSO-d6): δ 1.27 (s, 9H, (CH3)3),
1.36 (d, 2H, J = 5.28 Hz, CH2), 1.48 (m, 4H, (CH2)2), 2.51 (bs, 4H,
(CH2)2), 2.58 (t, 2H, J = 5.84 Hz, NeCH2), 3.96 (t, 2H, J = 5.84 Hz,
CH2), 4.65 (s, 1H, CH), 6.39 (d, 1H, J= 2.36 Hz, AreH), 6.45 (dd, 1H,
J= 2.32 Hz, 6.16 Hz, AreH), 6.77 (d, 2H, J= 8.48 Hz, AreH), 6.93 (d,
1H, J= 8.48 Hz, AreH), 7.01 (d, 2H, J= 8.76 Hz, AreH). 7.48 (s, 2H,
NH2), 9.56 (s, 1H, OH). 13C NMR (100 MHz, DMSO-d6): δ 23.93 (CH2),
25.56 (CH2), 28.11 (CH3), 38.58 (CH), 54.42 (CH2), 57.40 (CH2), 65.46
(CH2), 77.86 (C), 78.02 (C), 101.90 (CH), 111.92 (CH), 113.95 (CH),
116.94 (C), 127.87 (CH), 129.83 (CH), 141.18 (C), 148.85 (C), 156.47
(C), 156.52 (C), 160.52 (C), 168.50 (C]O). HRMS: Found 467.2551;
C27H35N2O5 requires 467.2546(M++H).
4.1.4.14. 2-Amino-7-hydroxy-4-[4-(2-morpholin-4-ylethoxy)phenyl]-4H-
chromeme-3-carboxylic methyl ester (42). Preparation as described for
39 above from 4-(2-morpholine-1-ylethoxy)benzaldehyde (31)
(5 mmol, 1.176 g), methyl cyanoacetate methyl cyanoacetate
(5 mmol, 495 mg) and resorcinol (5 mmol, 560 mg) using general
method C. Yield 226 mg, 10.6% as a brown oil. IR ʋmax (KBr) cm−1:
3432.55, 3367.14 (NH2), 1663.47 (C]O) cm−1. 1H NMR (400 MHz,
DMSO-d6): δ 1.07 (t, 3H, J= 7.02 Hz, CH3), 2.42 (s, 4H, (CH2)2), 2.62
(t, 2H, J= 5.52 Hz, CH2), 3.54 (t, 4H, J= 4.52 Hz, CH2), 3.96 (m, 4H,
2xCH2), 4.72 (s, 1H, CH), 6.41 (d, 1H, J = 2.00 Hz, AreH), 6.46 (dd,
1H, J = 2.26 Hz, 6.04 Hz, AreH), 6.78 (d, 1H, J = 8.52 Hz, AreH),
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6.93 (d, 2H, J = 8.04 Hz, AreH), 7.01 (d, 2H, J = 8.52 Hz, AreH),
7.60 (s(br), 2H, NH2), 9.65 (s, 1H, OH). 13C NMR (100 MHz, DMSO-d6):
δ 14.32 (CH3), 38.11 (CH), 53.60 (CH2), 57.04 (CH2), 58.53 (CH2),
65.13 (CH2), 66.14 (CH2), 76.81 (C), 101.99 (CH), 112.06 (CH), 114.03
(CH), 117.11 (C), 127.87 (CH), 129.76 (CH), 140.89 (C), 149.03 (C),
156.48 (C), 156.62 (C), 160.91 (C), 168.40 (C]O). HRMS: Found
427.1873; C23H27N2O6 requires 427.1869(M++H).
4.1.4.15. 2-Amino-7-hydroxy-4-[4-(2-morpholin-4-ylethoxy)phenyl]-4H-
chromeme-3-carboxylic ethyl ester (43). Preparation as described for 39
above following the general Method B from 4-(2-morpholine-1-
ylethoxy)benzaldehyde (31) (5 mmol, 1.176 g), ethyl cyanoacetate
(5 mmol, 565 mg) and resorcinol (5 mmol, 560 mg). Yield 24%, M.p.
144–146 °C, yellow powder. IR ʋmax (KBr) cm−1: 3425.00, 3285.02
(NH2), 1674.22 (C]O) cm−1. 1H NMR (400 MHz, DMSO-d6): δ 1.07 (t,
3H, J = 7.02 Hz, CH3), 2.42 (s, 4H, (CH2)2), 2.62 (t, 2H, J = 5.52 Hz,
CH2), 3.54 (t, 4H, J = 4.52 Hz, CH2), 3.96 (m, 4H, CH2), 4.72 (s, 1H,
CH), 6.41 (d, 1H, J = 2.00 Hz, AreH), 6.46 (dd, 1H, J = 2.26 Hz,
6.04 Hz, AreH), 6.78 (d, 1H, J = 8.52 Hz, AreH), 6.93 (d, 2H,
J = 8.04 Hz, AreH), 7.01 (d, 2H, J = 8.52 Hz, AreH), 7.60 (bs, 2H,
NH2), 9.65 (s, 1H, OH). 13C NMR (100 MHz, DMSO-d6): δ 14.32 (CH3),
38.11 (CH), 53.60 (CH2), 57.04 (CH2), 58.53 (CH2), 65.13 (CH2), 66.14
(CH2), 76.81 (C), 101.99 (CH), 112.06 (CH), 114.03 (CH), 117.11 (C),
127.87 (CH), 129.76 (CH), 140.89 (C), 149.03 (C), 156.48 (C), 156.62
(C), 160.91 (C), 168.40 (C]O). HRMS: Found 441.2044; C24H29N2O6
requires 441.2026(M++H).
4.1.4.16. 2-Amino-7-hydroxy-4-[4-(2-morpholin-4-ylethoxy)phenyl]-4H-
chromeme-3-carbonitrile (44). Preparation was as described for 39
above from 4-(2-morpholine-1-ylethoxy)benzaldehyde (31) (5 mmol,
1.176 g), malononitrile (5 mmol, 330 mg) and resorcinol (5 mmol,
560 mg) following the general method B. Yield 51%, M.p. 176 °C,
brown powder. IR ʋmax (KBr) cm−1: 3400.0, 3333.3 (NH2), 2187.7 (CN)
cm−1. 1H NMR (400 MHz, DMSO-d6): δ 2.36 (m, 4H, CH2), 2.57 (t, 2H,
J= 5.76 Hz, CH2), 3.36 (m, 4H, CH2), 3.95 (t, 2H, J = 5.76 Hz, CH2),
4.29 (bs, 2H, NH2), 4.47 (s, 1H, CH), 6.31 (d, 1H, J= 2.04 Hz, AreH),
6.39 (dd, 1H, J = 2.50 Hz, 6.04 Hz, AreH), 6.69 (d, 1H, J = 8.04 Hz,
AreH), 6.77 (t, 3H, J = 8.28 Hz, AreH), 6.97 (d, 1H, J = 8.52 Hz,
AreH). 13C NMR (100 MHz, DMSO-d6): δ 37.8 (CH), 53.61 (CH2), 56.04
(CH2), 56.53 (C), 65.21 (CH2), 66.16 (CH2), 102.10 (CH), 112.31 (CH),
114.05 (C), 114.45 (CH), 120.73 (C), 128.41 (CH), 129.91 (CH), 138.54
(C), 148.76 (C), 156.96 (C), 157.19 (C), 160.08 (C]O). HRMS: Found
394.1760; C22H24N3O4 requires 394.1767(M++H).
4.2. Stability study for compounds 38 and 40
Analytical high-performance liquid chromatography (HPLC) stabi-
lity studies were performed using a Symmetry® column (C18, 5 µm,
4.6 × 150 mm), a Waters 2487 Dual Wavelength Absorbance detector,
a Waters 1525 binary HPLC pump and a Waters 717plus Autosampler.
Samples were detected at wavelength of 254 nm. All samples were
analysed using acetonitrile (80%): water (20%) as the mobile phase
over 10 min and a flow rate of 1 mL/min. Stock solutions are prepared
by dissolving 5 mg of compound 38 and 40 in 10 mL of mobile phase.
Phosphate buffers at the desired pH values (4, 7.4, and 9) were pre-
pared in accordance with the British Pharmacopoeia monograph 2016.
30 µL of stock solution was diluted with 1 mL of appropriate buffer,
shaken and injected immediately. Samples were withdrawn and ana-
lysed at time intervals of t = 0 min, 5 min, 30 min, 60 min, 90 min,
120 min and 21 h.
4.3. Plasma stability study for compounds 38 and 40
Analytical high-performance liquid chromatography (HPLC) stabi-
lity studies for plasma samples were performed using a Waters HPLC
2965–2487 system with a Hypersil Gold column; l = 0.15 m,
i.d. = 4.6 mm, C18, 5 µm with flow rate: 1.0 mL/min, sample tem-
perature: 25 °C, column temperature: 25 °C; mobile phase
H2O:ACN:MeOH. Method 1: (10% DMSO): PBS (1.6 mL) added to blood
plasma (2.0 mL) and pre-warmed to 37 °C in a water bath. To this so-
lution, 400 µL of 1.0 mg/mL stock of compounds 38 and 41 was added.
Immediately a 100 µL aliquot was withdrawn and added to 900 µL
acetonitrile giving a final injection concentration of 0.01 mg/mL. The
samples were then centrifuged at 5000 rpm for 10 min and filtered
through a 0.2 µm filter and injected according to the HPLC conditions
listed above. Further samples were taken in the same manner every
15 min for the first hour and hourly thereafter up to 3 h. A final sample
was taken after 24 h.
4.4. Biochemical evaluation of activity
4.4.1. Antiproliferative studies
All assays were performed in triplicate for the determination of
mean values reported. Compounds were assayed as the free bases iso-
lated from reaction. The human breast cancer cell line MCF-7 was
cultured in Eagles minimum essential medium in air supplemented with
5% CO2 atmosphere with 10% fetal calf serum, 2 mM L-glutamine and
100 μg/mL penicillin/streptomycin The medium was supplemented
with 1% non-essential amino acids.
Cells were trypsinised and seeded at a density of 2.5 × 104 cells/mL
into a 96-well plate and incubated at 37 °C, in air supplemented with
5% CO2 atmosphere for 24 h. After this time they were treated with
2 µL volumes of test compound which had been pre-prepared as stock
solutions in ethanol to furnish the final concentration range of study,
1 nM-100 µM, and re-incubated for a further 72 h. Control wells con-
tained the equivalent volume of the vehicle ethanol (1% v/v). The
culture medium was then removed and the cells washed with 100 µL
phosphate buffer saline (PBS) and 50 µL of 1 mg/mL MTT solution was
added. Cells were incubated for 2 h in darkness at 37 °C. At this point
solubilisation was begun through the addition of 200 µL DMSO and the
cells maintained at room temperature in darkness for 20 min to ensure
thorough colour diffusion before reading the absorbance at 595 nm.
The absorbance value of control cells (vehicle treated) was set to 100%
cell viability and from this graphs of absorbance versus cell density per
well were prepared to assess cell viability and from these, graphs of
percentage cell viability versus concentration of subject compound
were drawn.
4.4.2. Lactate dehydrogenase assay for measurement of cytotoxicity
Cytotoxicity was determined using the CytoTox 96 nonradioactive
cytotoxicity assay (Promega) following the manufacturer’s protocol. In
this assay, the release of cytoplasmic lactate dehydrogenase (LDH) is
used as a measure of cell lysis. MCF-7 cells were seeded at a density of
1 × 104 cells/well in a 96-well plate and incubated for 24 h. The cells
were then dosed with 2 μL volumes of the test compounds, over the
concentration range 1 nM–50 μM. After dosing, the plates are incubated
for 72 h. Control wells contained the equivalent volume of the vehicle,
ethanol (1% v/v). After incubation, 30 μL of medium is removed from
each well and transferred to a fresh 96-well plate. To this, 30 μL of
substrate mix from the Promega cytotoxicity assay kit was added. The
plate was left in darkness for 20 min at room temperature. Stop solution
(30 μL) was added to the wells. The plates were read at a wavelength of
490 nm using an automated Molecular Devices micro-plate reader. A
positive control of 100% lysis was determined for a set of untreated
cells, which were lysed by the addition of lysis solution to the medium
45 min prior to harvesting. The percentage cell lysis was calculated for
the treated cells relative to the control data. Assays where repeated in
three experiments performed in triplicate (unless otherwise stated) and
reported results represent the mean value ± standard error mean. The
data was processed using PRISM(Version 4. Graphpad Software, Inc.,
2236 Avenida de la Playa, La Jolla, CA 92037, USA).
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4.4.3. Estrogen Receptor binding
ERα and ERβ fluorescence polarization based competitor assay kits
were obtained from Panvera at Invitrogen Life Technologies, Invitrogen
Corporation, 5791 Van Allen Way, PO Box 6482, Carlsbad, California
92008. The recombinant ER (insect expressed, full length, untagged
human ER obtained from recombinant baculovirus-infected insect cells)
and the fluorescent estrogen ligand were removed from the −80 °C
freezer and thawed on ice for one hour prior to use. The fluorescent
estrogen ligand (2 nM) was added to the ER (40 nM for ERα and 30 nM
for ERβ) and screening buffer (100 mM potassium phosphate (pH 7.4),
100 µg/mL BGG, 0.02% NaN3 was added to make up to a final volume
that was dependent on the number of tubes used (number of tubes (e.g.
50) × volume of complex in each tube (50 µL) = total volume (e.g.
2500 µL). Test compound (1 µL, concentration range 100 nM to 1 mM)
was added to 49 µL screening buffer in each borosilicate tube (6 mm
diameter). To this 50 µL of the fluorescent estrogen/ER complex was
added to make up a final volume of 100 µL. A vehicle control contained
1% (v/v) of ethanol; a negative control was used to determine the
theoretical maximum polarization (50 μL of screening buffer and 50 μL
of fluorescent estrogen/ER complex). The tubes were incubated in the
dark at room temperature for 2 h and were mixed by shaking on a plate-
shaker. Polarization values were measured on a Beacon single-tube
fluorescent polarization instrument fitted with 485 nm excitation and
530 nm emission interference filters. For ERα and ERβ, graphs of ani-
sotropy (mA) versus compound concentration were obtained for the
determination of IC50 values.
4.5. Computational procedures
All compounds were drawn in Accelrys Draw v4.188 with absolute
stereochemistry assigned for both R and S enantiomers. Enantiomers
were protonated at pH7.4 with MarvinView and subsequently con-
verted to 3D using Molconvert (version v15.6.29.0).82 10 conformers of
each 3D structure were subsequently enumerated using OMEGA (ver-
sion 2.5.1.4)89,90.
To establish a reliable model of ERβ, as no X-ray crystal structure of
human ERβ in an antagonist conformation currently exists, the se-
quence from Uniprot91 entry Q92731 (ESR2_HUMAN) was downloaded
and submitted to the iTASSER server.92,93 PDB entry 1R5K was speci-
fied as a template to guide the structure prediction. The resulting model
was submitted to the Yale Protein Multichain Morphing Server79 to
transform the atomic co-ordinates to those of PDB entry 1R5K. Finally,
3Drefine80,94,95 was used to refine our model of ERβ. PDB ID 2OUZ was
selected for modeling of the compound series in ERα as the co-crys-
tallised ligand (Lasofoxifene) was structurally similar to compound 35.
The iTASSER server was also used to model any missing residues with
2OUZ used to guide the structural prediction and again 3Drefine80,94,95
was used to refine our model of ERα. All conformers were docked using
FRED (OEDocking version 3.0.1)81,96 into the both Ligand Binding
Pockets (LBPs). Energy minimisation of the top scoring docked pose for
all enantiomers was performed using the Amber12:EHT force field
(gradient of 0.05 kcal/mol) as implemented in MOE (version
2012.10).97
4.6. X-Ray crystallography
Crystals of compound 22 were obtained by slow crystallisation from
a dilute solution of methanol over a period of 4–8 weeks. The data for
the crystal structures 22 were collected on a Rigaku Saturn 724 CCD
Diffractometer. A suitable crystal from each crystal compound was se-
lected and mounted using inert oil on a 0.3 mm diameter glass fiber tip
or loop and placed on the goniometer head in a 150 K N2 gas stream.
Each data set was collected using Crystalclear-SM 1.4.0 software. Data
integration, reduction and correction for absorption and polarization
effects were all performed using Crystalclear-SM 1.4.0 software. Space
group determination, structure solution and refinement were obtained
using Bruker Shelxtl Ver. 6.14 software.98 Each structure was solved
with Direct Methods using the SHELXTL program and refined against
IF2I with the program XL from SHELX-97 using all data. Non-hydrogen
atoms were refined with anisotropic thermal parameters. Hydrogen
atoms were placed into geometrically calculated positions and refined
using a riding model.
Crystal data for 22 are as follows: Empirical formula: C20H21NO5,
M = 355.38, T = 108(2) K, Wavelength 0.71075 Å, Crystal system:
Monoclinic, Space group: P 2/c, Unit cell dimensions: a = 16.982(7) Å,
b = 5.340(2) Å, c = 20.683(9) Å, α = 90°. β = 91.189(6)°, γ = 90°.
Volume: 1875.2(13) Å3 Z: 4, Density (calculated): 1.259 Mg/m3,
Absorption coefficient: 0.091 mm−1; F(0 0 0): 752; Crystal size:
0.240 × 0.210 × 0.180 mm3; Theta range for data collection: 2.328 to
24.999°. Index ranges −20 ≤ h ≤ 20, −5 ≤ k ≤ 6, –23 ≤ l ≤ 24;
Reflections collected: 13677, Independent reflections: 3240 [R
(int) = 0.0641]; Completeness to theta = 25.242°’; 95.2%; Absorption
correction: Semi-empirical from equivalents, max. and min. transmis-
sion: 1.0000 and 0.6725, Refinement method: Full-matrix least-squares
on F2, Data/restraints / parameters: 3240 / 0 / 238, Goodness-of-fit on
F2 :1.173, Final R indices: [I > 2sigma(I)]: R1 = 0.0840,
wR2 = 0.2055, R indices (all data): R1 = 0.1059, wR2 = 0.2203,
Extinction coefficient: n/a, Largest diff. peak and hole: 0.216 and
−0.253 e.Å−3. CCDC deposition CCDC 1014637.
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